CircRNA (Ribonucleic Acid) marker for exosome transport for inducing generation and / or development of bladder cancer by smoking and application of circRNA marker
By identifying the exosome transport circRNA marker hsa_circ_0055033 and its binding proteins in smoking-induced bladder cancer, the problem of lack of effective early diagnosis and prevention of bladder cancer in the prior art is solved, and efficient diagnosis and potential treatment of bladder cancer is achieved. Target discovery.
Patent Information
- Application Number
- CN202410892125.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-04
- Publication Date
- 2024-11-08
AI Technical Summary
The prior art lacks effective methods for early diagnosis and prevention of bladder cancer, especially in the occurrence and development of bladder cancer induced by smoking, and lacks novel markers and diagnostic and treatment methods.
A circRNA marker for smoking-induced exosome transport by inducing the occurrence and/or development of bladder carcinoma, specifically hsa_circ_0055033, and its binding to miR-1286, Ago2, EIF4A3, PTB and U2AF65, is proposed for the preparation of diagnostic or auxiliary diagnosis product.
hsa_circ_0055033 has been proven to be a marker for diagnosing or assisting the diagnosis of smoking-induced bladder cancer. It promotes the occurrence of bladder cancer through exosome enrichment and transport, has good diagnostic ability, and weakens the dryness and EMT marker expression of bladder cancer after knockdown. It reveals the new mechanism of smoking in the development of bladder cancer and provides new targets for early prevention and treatment.
Smart Images

Figure CN118910043A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of bladder cancer research, and particularly relates to a circRNA marker for exosome transport in the occurrence and / or development of smoking-induced bladder cancer and its application. Background Art
[0002] Bladder cancer is one of the most common malignant tumors of the urinary system. Although the diagnosis and treatment technology of bladder cancer has advanced rapidly, there is still a lack of effective early prevention and treatment targets. A small number of patients will still experience recurrence, metastasis and poor prognosis after surgery. Smoking is a very important risk factor for the occurrence and development of bladder cancer. Previous studies have found that smoking exposure can promote the EMT process and malignant transformation of bladder epithelial cells and enhance proliferation capacity, indicating that smoking plays an important role in the occurrence and development of bladder cancer. Exosomes can transport active molecules and play an important role in the occurrence and development of bladder cancer. It may become an important way to diagnose and treat bladder cancer to clarify whether cigarettes can promote the development of bladder cancer by affecting exosomes, and to explore whether the active ingredients carried by exosomes can become new markers for the diagnosis of smoking-induced bladder cancer.
[0003] At present, it is urgent to explore new molecular mechanisms, non-invasive diagnostic markers and early prevention and treatment strategies for the occurrence and development of bladder cancer in clinical practice. Exosomes are a type of extracellular vesicles with a diameter of 30 to 150 nm. They are widely and stably present in urine and blood and can reflect the physiological and pathological conditions of the body. Exosomes can transport active substances and participate in the occurrence and development of tumors such as bladder cancer. Exosomes stimulate the tube formation and migration of lymphatic endothelial cells by transporting lncLNMAT2, promoting bladder cancer lymphangiogenesis and lymphatic metastasis. Zheng et al. reported that BCYRN1 derived from exosomes can synergistically enhance the activity of the VEGF-C / VEGFR3 signaling pathway, thereby inducing lymphatic metastasis of bladder cancer. Exosome-transported miR-21 inhibits the activation of phosphatases and tensin homologs of the PI3K / AKT pathway in macrophages, and enhances STAT3 expression to promote M2 phenotype polarization, thereby promoting the progression of bladder cancer. The above studies show that exploring the role of exosomes in transporting specific active molecules in the occurrence and development of bladder cancer may reveal new mechanisms of bladder cancer occurrence and development, and may also discover new diagnostic and therapeutic markers.
[0004] CircRNA is a type of non-coding RNA that plays an important role in human life activities. Multiple circRNAs are abnormally expressed in bladder cancer and are closely related to the occurrence and development of bladder cancer. CircFAM13B is expressed at a low level in bladder cancer tissues, which is positively correlated with lower tumor stage and better prognosis in bladder cancer patients. Circ NCOR1 is significantly downregulated in lymph node metastatic bladder cancer, and overexpression of circNCOR1 significantly inhibits bladder cancer growth and lymph node metastasis. Circ0068307 is highly expressed in bladder cancer, and circPTK2 can bind to PAPC1 and enhance its ability to stabilize SETDB1mRNA, thereby specifically promoting SETDB1-mediated EMT and bladder cancer progression. However, the role of circRNA in promoting the occurrence and development of bladder cancer by affecting exosomes has not been reported. Summary of the invention
[0005] In view of the above problems, one of the objectives of the present invention is to propose a circRNA marker for exosome transport of smoking-induced bladder cancer occurrence and / or development, wherein the circBase ID of the exosome circRNA marker is hsa_circ_0055033, and the nucleotide sequence is shown in SEQ ID NO: 1.
[0006] The second purpose of the present invention is to propose the use of hsa_circ_0055033 in the preparation of products for diagnosing or assisting in diagnosing the occurrence and / or development of smoking-induced bladder cancer.
[0007] Furthermore, the product comprises a primer pair for recognizing the exosome circRNA marker, the forward nucleotide sequence of the primer pair is shown in SEQ ID NO:4, and the backward nucleotide sequence is shown in SEQ ID NO:5.
[0008] Furthermore, the product is selected from a preparation, a chip or a kit.
[0009] The third purpose of the present invention is to propose the use of hsa_circ_0055033 combined with miR-1286 in the preparation of products for diagnosing or assisting in diagnosing the occurrence and / or development of smoking-induced bladder cancer.
[0010] Furthermore, the specific binding sites of the circRNA marker and miR-1286 are as follows:
[0011] hsa circ 0055033(5'...3')CUCAAUUUUGAAGAA GUCCUGC A;
[0012] hsa-miR-1286(3'...5')UCCCGAGUAGAAC CAGGACG U.
[0013] The fourth object of the present invention is to propose the use of hsa_circ_0055033 combined with Ago2 protein in the preparation of products for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
[0014] The fifth object of the present invention is to propose the use of hsa_circ_0055033 combined with EIF4A3 in the preparation of products for diagnosing or assisting in diagnosing the occurrence and / or development of smoking-induced bladder cancer.
[0015] The sixth object of the present invention is to propose the use of hsa_circ_0055033 combined with PTB in the preparation of products for diagnosing or assisting in diagnosing the occurrence and / or development of smoking-induced bladder cancer.
[0016] The seventh object of the present invention is to propose the use of hsa_circ_0055033 combined with U2AF65 in the preparation of products for diagnosing or assisting in diagnosing the occurrence and / or development of smoking-induced bladder cancer.
[0017] Beneficial effects of the present invention:
[0018] The present invention first discovered that hsa_circ_0055033 can be used as a marker for diagnosing or assisting in the diagnosis of smoking-induced bladder cancer occurrence and / or development, and promotes bladder cancer occurrence through exosomes enrichment and transport of the above circRNAs, which has certain clinical application value in the diagnosis of bladder cancer; the ROC curve shows that hsa_circ_0055033 has a good ability to diagnose the occurrence and / or development of smoking-induced bladder cancer. At the same time, it was found that smoking can promote the expression of hsa_circ_0055033 in bladder cancer cells. After knocking down hsa_circ_0055033, smoking-induced exosomes promote the weakening of bladder cancer stemness and the reduction of EMT marker expression. The role and diagnostic value of new exosome circRNAs in the development of smoking-induced bladder cancer can reveal a new mechanism by which smoking promotes the occurrence of bladder cancer and provide new targets for the early prevention and treatment of bladder cancer.
[0019] Other features and advantages of the present invention will be described in the following description, and partly become apparent from the description, or understood by practicing the present invention. The purpose and other advantages of the present invention can be realized and obtained by the structures pointed out in the description, claims and drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0020] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following briefly introduces the drawings required for use in the embodiments or the description of the prior art. Obviously, the drawings described below are some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0021] Figure 1A It was shown that smoking promotes the expression of stemness and EMT marker proteins in UM-UC-3 cells;
[0022] Figure 1B It was shown that smoking promotes the expression of EJ cell stemness and EMT marker proteins;
[0023] Figure 1C The effect of smoking on the mRNA expression of stemness and EMT markers in UM-UC-3 cells is shown;
[0024] Figure 1D The effect of smoking on the mRNA expression of EJ cell stemness and EMT markers is shown;
[0025] Figure 2A It was shown that smoking-induced BCs-ex promoted the expression of stemness and EMT marker proteins in UM-UC-3 cells;
[0026] Figure 2B It was shown that smoking-induced BCs-ex promoted the expression of EJ cell stemness and EMT marker proteins;
[0027] Figure 2C The effects of smoking-induced BCs-ex on the mRNA expression of stemness and EMT markers in UM-UC-3 cells are shown;
[0028] Figure 2D The effects of smoking-induced BCs-ex on the mRNA expression of EJ cell stemness and EMT markers are shown;
[0029] Figure 3A The results of circRNA chip detection in bladder cancer tissue and adjacent tissue of patients with a history of smoking are shown;
[0030] Figure 3B It shows that circRNAs in bladder cancer cells are abnormally highly expressed;
[0031] Figure 3C It was shown that smoking upregulated the expression of circRNAs in BCs-ex;
[0032] Figure 3D The expression levels of circRNAs in bladder cancer tissues of patients with a history of smoking are shown;
[0033] Figure 4A The diagnostic efficacy of circ55033 in bladder cancer with a smoking history is shown, n = 38;
[0034] Figure 4B The diagnostic efficacy of circ878551 in bladder cancer with a smoking history is shown, n = 38;
[0035] Figure 5A A schematic diagram of the Circ55033 knockdown reduction interference construct is shown;
[0036] Figure 5B The expression level of circ55033 in BCs-ex after knockdown is shown;
[0037] Figure 5C The effect of BCs-ex on the mRNA expression of stemness genes and EMT markers after knockdown of circ55033 is shown;
[0038] Fig. 6A The expression of Circ55033 in the cytoplasm and nucleus is shown;
[0039] Figure 6B The detection of the ability of Circ55033 to bind to AGO2 is shown;
[0040] Figure 6C The luciferase reporter gene experiment screening for binding to miRNA is shown;
[0041] Fig.6D The binding sites of Circ55033 and miR-1286 are shown;
[0042] Fig. 6E The expression level of miR-12868 in bladder cancer and bladder cancer stem cells is shown;
[0043] Fig. 6F The effect of transfection of miR-1286 mimics on the expression of bladder cancer stem cell stemness and EMT markers is shown;
[0044] Figure 6G The TRAP and Western blot experiments were performed to analyze the circ55033 binding proteins. DETAILED DESCRIPTION
[0045] In order to make the purpose, technical solution and advantages of the embodiments of the present invention clearer, the technical solution in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0046] Unless otherwise specified in the following examples, the reagents and biological materials used are all commercially available. If no specific conditions are specified in the examples, the experiments were carried out according to conventional conditions or the conditions recommended by the manufacturer. Molecular biology experimental methods not specifically described in the examples were carried out according to the specific methods listed in the book Molecular Cloning Laboratory Manual (3rd Edition) by J. Sambrook, or according to the kits and product instructions.
[0047] Example 1
[0048] The cigarette exposure model of bladder cancer cells was established as follows:
[0049] The cigarette was continuously inhaled by a negative pressure drive device and burned out within 5 minutes. The cigarette smoke was dissolved in the cell culture medium by suction to make a suspension, which was sealed and shaken evenly. The pH value was adjusted to 7.4, and the suspension was sterilized by microporous filter membrane for later use. The concentration of one cigarette / 10 mL of culture medium was 100%, and the concentration was diluted as required.
[0050] Cigarette smoke suspension was freshly prepared daily, and bladder cancer cells were treated with different concentrations of cigarette smoke suspension for different time periods to observe the dose- and time-effect relationships.
[0051] Example 2
[0052] The bladder cancer cell cigarette exposure model established in Example 1 was used to explore the effect of cigarette exposure on the stemness and EMT (epithelial-mesenchymal transition) of bladder cancer cells. The specific method is as follows:
[0053] UM-UC-3 (human bladder transitional cell carcinoma cell) and EJ (human bladder cancer cell) cells in suspension culture were treated with 0% CES (control) and 0.5% cigarette smoke suspension (0.5% CES) for 4 consecutive days to observe the effect of smoking on the stemness and EMT of bladder cancer cells (the bladder cancer cells mentioned below include UM-UC-3 and EJ);
[0054] RNA and protein were extracted from bladder cancer cells treated with different concentrations of cigarette smoke suspensions, and the effects of smoking on the mRNA and protein expression levels of bladder cancer stem cell markers (including CD44, Nanog, Oct-4, ALDH1, E-cadherin, Vimentin, and GAPDH) were detected.
[0055] RNA and protein were extracted from bladder cancer cells treated with cigarette smoke suspensions of different concentrations, and the effects of cigarette exposure on the mRNA and protein expression levels of EMT markers such as E-cadherin, ZO-1, Vimentin, and N-cadherin were observed to clarify the promoting effect of cigarette exposure on the EMT process of bladder cancer cells.
[0056] The results are as follows Figures 1A-1D As shown in the data, it can be seen that smoking exposure can significantly upregulate the expression levels of bladder cancer cell (UM-UC-3 and EJ) markers Nanog, OCT4, ALDH1, and CD44; smoking exposure can significantly downregulate the expression level of bladder cancer cell marker E-cadherin and upregulate the expression of stromal cell marker Vimentin, suggesting that smoking exposure can promote the stemness and EMT process of bladder cancer cells.
[0057] Example 3
[0058] The bladder cancer cell cigarette exposure model established in Example 1 was used to explore the effect of smoking-induced BCs-ex on promoting the stemness and EMT process of bladder cancer cells. The specific method is as follows:
[0059] Serum-free suspension cultured bladder cancer cells (UM-UC-3 and EJ) were treated with 0% (control) and 0.5% cigarette smoke suspension for 4 consecutive days. Exosomes (BCs-ex) secreted by bladder cancer cells treated with cigarette smoke suspension were extracted and used to treat UM-UC-3 and EJ cells (0.5% CES-Ex) to observe their effects on bladder cancer cell stemness and EMT.
[0060] RNA and protein were extracted from bladder cancer cells (UM-UC-3 and EJ) treated with different groups of exosomes, and the effects of exosomes on the mRNA and protein expression levels of bladder cancer stem cell markers were detected;
[0061] Bladder cancer cells treated with different groups of exosomes were made into single-cell suspensions, and the cells were incubated with fluorescein-labeled CD44 antibodies. Flow cytometry was used to detect the number of bladder cancer cells with positive CD44 markers.
[0062] The effects of exosomes on the mRNA and protein expression levels of EMT markers were observed, and their migration and invasion abilities were detected using Transwell assays to clarify the role of exosomes in promoting the EMT process of bladder cancer cells.
[0063] The results are as follows Figures 2A-2DAs shown in the figure, it can be seen that smoking-induced BCs-ex significantly upregulated the expression levels of Nanog, CD44, and ALDH1, the stemness markers of bladder cancer cells ( Figure 2A and 2B ); Smoking exposure can significantly downregulate the expression level of E-cadherin, a bladder cancer cell marker ( Figure 2C and 2D ), suggesting that smoking exposure can promote the EMT process of bladder cancer stem cells. These phenomena indicate that smoking-induced BCs-ex promotes the stemness and EMT process of bladder cancer cells.
[0064] Based on the clarification of the role of exosomes in smoking-induced promotion of bladder cancer cell stemness and EMT, we further screened and verified the key circRNAs transported by exosomes, and confirmed their role in smoking-induced promotion of bladder cancer cell stemness and EMT.
[0065] Example 4
[0066] Screening of exosomal circRNA markers for the occurrence and / or development of smoking-induced bladder cancer, the specific method is as follows:
[0067] Based on the circRNA chip detection data of bladder cancer tissue and adjacent tissue of patients with a history of smoking, highly expressed circRNAs were screened. The chip detection results are as follows Figure 3A As shown, hsa_circ_0055033, hsa_circ_0087855, and hsa_circ_0007521 (hereinafter referred to as circ55033, circ87855, and circ07521, respectively) were significantly highly expressed;
[0068] Based on the above test results, further studies were conducted on bladder cancer cells ( Figure 3B )、BCs-ex( Figure 3C ) and bladder cancer tissues (3D), it can be seen that circ55033, circ87855 and circ07521 are significantly more expressed in bladder cancer cells and bladder cancer tissues compared with their expression in normal cells SV-HUC-1. Therefore, circ55033, circ87855 and circ07521 can be used for the diagnosis of smoking-induced bladder cancer occurrence and / or development.
[0069] The nucleotide sequences of circ55033, circ87855 and circ07521 are shown in SEQ ID NO: 1, SEQ ID NO: 2 and SEQ ID NO: 3, respectively.
[0070] SEQ ID NO: 1 is as follows:
[0071] CTGGCCCGGATTGCGGACAGTAAGGATCATGTGTTTCCCGTGAATGACGGCTTTCAGGCTCTGCAAGG
[0072] CATCATCCACTCAATTTTGAAGAAGTCCTGCATCGAAATTCTAGCAGCTGAACCATCCACCATATGTG
[0073] CAGGAG
[0074] SEQ ID NO:2 is as follows:
[0075] GTGAAAGCACTGAAAGAGAAGATTGAATCTGAAAAGGGGAAAGATGCCTTTCCAGTAGCAGGTCAAAA
[0076] ATTAATTTATGCAGGCAAAATCCTCAATGATGATACTGCTCTCAAAGAATATAAAATTGATGAGAAAA
[0077] ACTTTGTGGTGGTTATGGTGACCAAACCCAAAGCAGTGTCCACACCAGCACCAGCTACAACTCAGCAG
[0078] TCAGCTCCTGCCAGCACTACAGCAGTTACTTCCTCCACCACCACAACTGTGGCTCAGGCTCCAACCCC
[0079] TGTCCCTGCCTTGGCCCCCACTTCCACACCTGCATCCATCACTCCAGCATCAGCGACAGCATCTTCTG
[0080] AACCTGCACCTGCTAGTGCAGCTAAACAAGAGAAGCCTGCAGAAAAGCCAGCAGAGACACCAGTGGCT
[0081] ACTAGCCCAACAGCAACTGACAG
[0082] SEQ ID NO:3 is as follows:
[0083] AATATGACAGATACCTAGCATCTAGCAAAATAATGGCAGCTGCTTACCTTGACCCCAACTTGAATCAC
[0084] ACACCAAATTCGAGTACTAAGACTCACCTGGGTACTGGTATGGAACGTTCTCCTGGTGCAATGGAGCG
[0085] AGTATTAAAGGTCTTTCATTATTTTGAAAGCAATAGTGAGCCAACCACCTGGGCCAGTATTATCAGGC
[0086] ATGGAGATGCTACTGATGTCAGGGGCATCATTCAGAAGATAGTGGACAGTCACAAAGTAAAGCATGTG
[0087] GCCTGCTATGGATTCCGCCTCAGTCACCTGCGGTCAGAGGAGGTTCACTGGCTTCACGTGGATATGGG
[0088] CGTCTCCAGTGTGAGGGAGAAGTATGAGCTTGCTCACCCACCAGAGGAGTGGAAATATGAATTGAGAA
[0089] TTCGTTATTTGCCAAAAGGATTTCTAAACCAGTTTACTGAAGATAAGCCAACTTTGAATTTCTTCTAT
[0090] CAACAGGTGAAGAGCGATTATATGTTAGAGATAGCTGATCAAGTGGACCAGGAAATTGCTTTGAAGTT
[0091] GGGTTGTCTAGAAATACGGCGATCATACTGGGAGATGCGGGGCAATGCACTAGAAAAGAAGTCTAACT
[0092] ATGAAGTATTAGAAAAAGATGTTGGTTTAAAGCGATTTTTTCCTAAGAGTTTACTGGATTCTGTCAAG
[0093] GCCAAAACACTAAGAAAACTGATCCAACAAACATTTAGACAATTTGCCAACCTTAATAGAGAAGAAAG
[0094] TATTCTGAAATTCTTTGAGATCCTGTCTCCAGTCTACAGATTTGATAAGGAATGCTTCAAGTGTGCTC
[0095] TTGGTTCAAGCTGGATTATTTCAGTGGAACTGGCAATCGGCCCAGAAGAAGGAATCAGTTACCTAACG
[0096] GACAAGGGCTGCAATCCCACACATCTTGCTGACTTCACTCAAGTGCAAACCATTCAGTATTCAAACAG
[0097] TGAAGACAAGGACAGAAAAGGAATGCTACAACTAAAAATAGCAGGTGCACCCGAGCCTCTGACAGTGA
[0098] CGGCACCATCCCTAACCATTGCGGAGAATATGGCTGACCTAATAGATGGGTACTGCCGGCTGGTGAAT
[0099] GGAACCTCGCAGTCATTTATCATCAGACCTCAGAAAG
[0100] Example 5
[0101] The validation of the diagnostic effect of exosomes transporting circRNAs in bladder cancer with a history of smoking was as follows:
[0102] With the approval of the Medical Ethics Committee and after obtaining informed consent from the patients, serum exosomes from 38 bladder cancer patients with a history of smoking and 38 healthy subjects treated in our hospital between 2020 and 2023 were collected for qRT-PCR analysis. The specific process is as follows:
[0103] Trizol (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from cells and tissues. Qiagen kit method (Invitrogen, Carlsbad, CA, USA) was used to extract total RNA from exosomes. Vazyme HiScriptⅡcDNA Synthesis (Vazyme, Jiangsu, China) was used as reverse transcription kit. Vazyme AceQ SYBR Green Master Mix qRT-PCR (Vazyme, Jiangsu, China) was used as fluorescence quantitative PCR kit. PCR reaction was performed using ABI 7500 real-time fluorescence quantitative PCR instrument (Applied Biosystems, Foster City, CA, USA). GAPDH was used as internal reference. 2 -ΔΔCt The relative RNA expression was calculated by the method; the primers were synthesized by Sangon Biotechnology (Shanghai) Co., Ltd., and the primer sequences are as follows:
[0104] Forward (SEQ ID NO:4): CATCCACCATATGTGCAGGAGCTGG;
[0105] Backward (SEQ ID NO:5): ATCCTTACTGTCCGCAATCC.
[0106] ROC curve analysis:
[0107] Methodological evaluation and quality assessment were conducted in terms of accuracy, precision, linear range and anti-interference ability, and the diagnostic value (including cut-off value, sensitivity, specificity, positive predictive value, negative predictive value) and diagnostic specificity of exosomes transport circRNAs were evaluated, and compared with pathological examination indicators, and the combined diagnostic efficacy of each candidate exosomes transport circRNAs was detected. The ROC curve of serum exosomes circ55033 ( Figure 4A ) was 0.6972 (sensitivity = 65.56%, specificity = 78.18%), and the ROC curve of circ87855 ( Figure 4B ) was 0.7018 (sensitivity = 69.21%, specificity = 77.62%).
[0108] ROC curve analysis showed that the detection of circ55033 and circ87855 in serum exosomes had diagnostic value in bladder cancer with a history of smoking.
[0109] Example 6
[0110] Exosomes transport circRNAs to regulate smoking-induced bladder cancer cell stemness and EMT. The verification of circ55033 is used as an example. The specific method is as follows:
[0111] according to Figure 5A The schematic diagram of the construction shown is that circ55033 was knocked down in bladder cancer stem cells using small interfering RNA, and BCs-ex secreted by bladder cancer stem cells were extracted. Circ55033 was knocked down in bladder cancer stem cells (UM-UC-3-BCSCs and EJ-BCSCs), BCs-ex secreted by bladder cancer stem cells were extracted, and the expression of circ55033 was detected. The results are shown in Figure 5B As shown, Control is the group without any treatment, NC is the small interfering RNA solvent control - RNase-free water, Si1-100nm and Si2-100nm are small interfering RNAs of different doses, and it was found that circ55033 was significantly inhibited;
[0112] Using 3×10 8 BCs-ex with high particle count and BCs-ex with circ55033 knockdown were added to the bladder cancer cell culture system and cultured for 48 hours. Figure 5C As shown in the data, it was shown that the effect of BCs-ex with circ55033 knockdown on enhancing the stemness of bladder cancer stem cells was weakened, suggesting that BCs-ex may play a regulatory role in enhancing the stemness of bladder cancer stem cells by transporting circ55033.
[0113] Example 7
[0114] Nuclear-cytoplasmic separation experiments were used to analyze the localization of circ55033 in cells, and the key miRNAs and proteins bound to it were screened and verified.
[0115] The specific process of the nuclear-cytoplasmic separation experiment is as follows:
[0116] (1) Add an appropriate amount of Trizol to the cell pellet and extract the RNA from the cell nucleus according to the steps for extracting cellular RNA;
[0117] (2) Add 600 μL of Buffer RLT to the EP tube containing the supernatant and vortex to mix;
[0118] (3) Add 430 μL of anhydrous ethanol to the mixed solution in the EP tube;
[0119] (4) Transfer the sample mixture to a 2 mL adsorption column and centrifuge at 10,000 rpm for 15 s. Discard the waste liquid in the collection tube and repeat this operation until the entire sample mixture is centrifuged.
[0120] (5) Add 700 μL of Buffer RW1 to the adsorption column, centrifuge at 10,000 rpm for 15 s to wash the adsorption column membrane, and discard the waste liquid in the collection tube;
[0121] (6) Add 500 μL of Buffer RPE, centrifuge at 10,000 rpm for 15 s to wash the adsorption column membrane again, and discard the waste liquid in the collection tube;
[0122] (7) Add 500 μL of Buffer RPE, centrifuge at 10,000 rpm for 2 min, and discard the collection tube containing the waste liquid;
[0123] (8) Place the adsorption column in a new 2 mL collection tube, centrifuge at 10,000 rpm for 1 min, and discard the collection tube;
[0124] (9) The adsorption column was reinstalled in a new 1.5 mL EP tube, 30-50 μL of RNase-free water was added to the middle membrane of the adsorption column, and the column was centrifuged at 10,000 rpm for 1 min. The RNA collected in the EP tube was used for subsequent RIP experiments.
[0125] The results of the nuclear-cytoplasmic separation experiment are as follows Fig. 6A As shown in the results, circ55033 is mainly expressed in the cytoplasm, suggesting that circ55033 may exert its biological function mainly by binding to miRNA.
[0126] According to Gisele The RIP experiment was performed according to the instructions of the lmmunoprecipitation Kit. The results were as follows Figure 6B As shown, the results showed that circ55033 could bind to Ago2 protein.
[0127] The miRNAs with potential to bind to circ55033 were predicted by bioinformatics software (circbank and circinteractome databases). Figure 6C ), further verification revealed that miR-1286 had a strong inhibitory effect on the activity of the circ55033 luciferase reporter gene and had a large number of binding sites ( Fig.6D ), the specific binding sites of the circRNA marker and miR-1286 are as follows:
[0128] hsa circ 0055033(5'...3')CUCAAUUUUGAAGAA GUCCUGC A (SEQ ID NO: 6);
[0129] hsa-miR-1286(3'...5')UCCCGAGUAGAAC CAGGACG U (SEQ ID NO: 7).
[0130] The expression level of miR-1286 in bladder cancer and bladder cancer stem cells was verified, and it was found that the expression of miR-1286 in bladder cancer cells and bladder cancer stem cells was significantly reduced ( Fig. 6E ).
[0131] Transfection of miR-1286 mimics to UM-UC-3 ( Fig. 6F Left) and EJ cells ( Fig. 6F The results showed that overexpression of miR-1286 could inhibit the expression of stemness genes in bladder cancer cells.
[0132] TRAP kit and Western blot (protein immunoassay) were used to analyze the binding of circ55033 to proteins. Figure 6G As shown, circ55033 was found to have binding ability with PTB, U2AF65 and EIF4A3, and its binding ability with EIF4A3 was the strongest.
[0133] Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or make equivalent substitutions for some of the technical features therein; and these modifications or substitutions do not make the essence of the corresponding technical solutions deviate from the spirit and scope of the technical solutions of the embodiments of the present invention.
Claims
1. A circRNA marker for exosome transport in the occurrence and / or development of smoking-induced bladder cancer, characterized in that: The circBase ID of the exosome circRNA marker is hsa_circ_0055033, and the nucleotide sequence is shown in SEQ ID NO:
1.
2. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
3. The use according to claim 2, characterized in that: The product comprises a primer pair for recognizing the exosomal circRNA marker; The forward nucleotide sequence of the primer pair is shown in SEQ ID NO:4, and the backward nucleotide sequence is shown in SEQ ID NO:
5.
4. The use according to claim 3, characterized in that: The product is selected from a preparation, a chip or a kit.
5. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in combination with miR-1286 in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
6. The use according to claim 5, characterized in that: The specific binding sites of the circRNA marker and miR-1286 are as follows: hsa circ 0055033(5'...3') CUCAAUUUUGAGAAA GUCCUGC A: hsa-miR-1286(3'...5')UCCCGAGUAGAAC CAGGACG U。 7. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in combination with Ago2 protein in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
8. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in combination with EIF4A3 in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
9. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in combination with PTB in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
10. Use of the exosome-transported circRNA marker for the occurrence and / or development of smoking-induced bladder cancer as claimed in claim 1 in combination with U2AF65 in the preparation of a product for diagnosing or assisting in the diagnosis of the occurrence and / or development of smoking-induced bladder cancer.
Citation Information
Cited By
Exosome action path recognition system and method fused with smoking induction factor
CN121528551A
An exosome acting path recognition system and method of a smoking inducer fusion
CN121528551B
